Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Nektar Therapeutics (Nasdaq: NKTR) will participate in the 2026 Jefferies Global Healthcare Conference in New York.
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) will participate in the 2026 Jefferies Global Healthcare Conference in New York. Management’s fireside chat is scheduled for Wednesday, June 3, 2026 at 1:20 p.m. ET and will be webcast live.
The webcast and 30-day replay will be accessible via Nektar’s investor events webpage.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NKTR
On May 28, the first trading day after this news, NKTR closed 0.60% below the previous close.
Data tracked by StockTitan Argus for the May 28 session.
Key Figures
- Conference dates
- June 2-4, 2026
- Jefferies Global Healthcare Conference timing
- Webcast date
- June 3, 2026
- Nektar fireside chat webcast date
- Webcast time
- 1:20 p.m. Eastern Time
- Scheduled time for conference fireside chat webcast
- Replay period
- 30 days
- Duration webcast replay will remain available
Historical Context
-
Reported Q1 2026 results with large cash balance and ongoing Phase 3 plans.
-
Announced stock options and RSUs for six newly hired employees.
-
Set date and time to release and discuss Q1 2026 financial results.
-
Closed $373.8M underwritten public offering of common stock under S-3ASR.
-
Priced upsized $325M public offering to fund R&D and Phase 3 trials.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 2026 Jefferies Global Healthcare Conference in
New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the fireside chat will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york-302783711.html
SOURCE Nektar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.